Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T, Cao J, Zou F, Li X, Wang A, Wang W, Liang H, Liu Q, Hu C, Chen C, Hu Z, Wang W, Li L, Ge J, Shen Y, Ren T, Liu J, Xia R, Liu Q.
Lu T, et al. Among authors: li x, li l.
Eur J Pharmacol. 2021 Apr 15;897:173944. doi: 10.1016/j.ejphar.2021.173944. Epub 2021 Feb 11.
Eur J Pharmacol. 2021.
PMID: 33581133